FDA
-
-
-
-
-
-
-
Candel Therapeutics to present prostate cancer data at ASTRO 2026
-
-
-
-
-
-
-
Candel Therapeutics names Mark Sims as chief commercial officer
-
-
-
-
-
-
-
Candel Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
-
-
-
-
-
-
-
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
-
-
-
-
-
-
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
-
-
-
-
-
-
Candel Therapeutics Announces $100M Royalty Funding Agreement with RTW to Support the Potential Launch of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer
-
-
-
-
-
-
-
Candel Therapeutics Showcases Immunotherapy Leadership at SITC 2025, Demonstrating Integration of Clinical Innovation, Multi-Omics, and Artificial Intelligence to Advance Next-Generation Immunotherapi
-
330,751 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

